BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Niu C, Li M, Zhu S, Chen Y, Zhou L, Xu D, Xu J, Li Z, Li W, Cui J. PD-1-positive Natural Killer Cells have a weaker antitumor function than that of PD-1-negative Natural Killer Cells in Lung Cancer. Int J Med Sci 2020;17:1964-73. [PMID: 32788875 DOI: 10.7150/ijms.47701] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Riera Romo M. Cell death as part of innate immunity: Cause or consequence? Immunology 2021;163:399-415. [PMID: 33682112 DOI: 10.1111/imm.13325] [Reference Citation Analysis]
2 Jacquelot N, Ghaedi M, Warner K, Chung DC, Crome SQ, Ohashi PS. Immune Checkpoints and Innate Lymphoid Cells-New Avenues for Cancer Immunotherapy. Cancers (Basel) 2021;13:5967. [PMID: 34885076 DOI: 10.3390/cancers13235967] [Reference Citation Analysis]
3 Lee H, Da Silva IP, Palendira U, Scolyer RA, Long GV, Wilmott JS. Targeting NK Cells to Enhance Melanoma Response to Immunotherapies. Cancers (Basel) 2021;13:1363. [PMID: 33802954 DOI: 10.3390/cancers13061363] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Munari E, Mariotti FR, Quatrini L, Bertoglio P, Tumino N, Vacca P, Eccher A, Ciompi F, Brunelli M, Martignoni G, Bogina G, Moretta L. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. Int J Mol Sci 2021;22:5123. [PMID: 34066087 DOI: 10.3390/ijms22105123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Toffoli EC, Sheikhi A, Höppner YD, de Kok P, Yazdanpanah-Samani M, Spanholtz J, Verheul HMW, van der Vliet HJ, de Gruijl TD. Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. Cancers (Basel) 2021;13:711. [PMID: 33572396 DOI: 10.3390/cancers13040711] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Versteven M, Flumens D, Campillo-davó D, De Reu H, Van Bruggen L, Peeters S, Van Tendeloo V, Berneman Z, Dolstra H, Anguille S, Hobo W, Smits E, Lion E. Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands. Front Immunol 2022;13:734256. [DOI: 10.3389/fimmu.2022.734256] [Reference Citation Analysis]
7 Pesce S, Trabanelli S, Di Vito C, Greppi M, Obino V, Guolo F, Minetto P, Bozzo M, Calvi M, Zaghi E, Candiani S, Lemoli RM, Jandus C, Mavilio D, Marcenaro E. Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes. Cancers (Basel) 2020;12:E3504. [PMID: 33255582 DOI: 10.3390/cancers12123504] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
8 Fatima S, Ma Y, Safrachi A, Haider S, Spring KJ, Vafaee F, Scott KF, Roberts TL, Becker TM, de Souza P. Harnessing Liquid Biopsies to Guide Immune Checkpoint Inhibitor Therapy. Cancers 2022;14:1669. [DOI: 10.3390/cancers14071669] [Reference Citation Analysis]
9 Zhu H, Liu X. Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies. Front Oncol 2021;11:666340. [PMID: 34434889 DOI: 10.3389/fonc.2021.666340] [Reference Citation Analysis]
10 Gemelli M, Noonan DM, Carlini V, Pelosi G, Barberis M, Ricotta R, Albini A. Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer. Front Oncol 2022;12:886440. [DOI: 10.3389/fonc.2022.886440] [Reference Citation Analysis]
11 Knab VM, Gotthardt D, Klein K, Grausenburger R, Heller G, Menzl I, Prinz D, Trifinopoulos J, List J, Fux D, Witalisz-Siepracka A, Sexl V. Triple-negative breast cancer cells rely on kinase-independent functions of CDK8 to evade NK-cell-mediated tumor surveillance. Cell Death Dis 2021;12:991. [PMID: 34689158 DOI: 10.1038/s41419-021-04279-2] [Reference Citation Analysis]
12 Ishiguro S, Upreti D, Bassette M, Singam ERA, Thakkar R, Loyd M, Inui M, Comer J, Tamura M. Local immune checkpoint blockade therapy by an adenovirus encoding a novel PD-L1 inhibitory peptide inhibits the growth of colon carcinoma in immunocompetent mice. Transl Oncol 2022;16:101337. [PMID: 34990908 DOI: 10.1016/j.tranon.2021.101337] [Reference Citation Analysis]
13 Niu C, Chen Y, Li M, Zhu S, Zhou L, Xu D, Li Z, Xu J, Li W, Wang Y, Cui J. Non-Coated Rituximab Induces Highly Cytotoxic Natural Killer Cells From Peripheral Blood Mononuclear Cells via Autologous B Cells. Front Immunol 2021;12:658562. [PMID: 34113342 DOI: 10.3389/fimmu.2021.658562] [Reference Citation Analysis]
14 Brauneck F, Seubert E, Wellbrock J, Schulze Zur Wiesch J, Duan Y, Magnus T, Bokemeyer C, Koch-Nolte F, Menzel S, Fiedler W. Combined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML. Int J Mol Sci 2021;22:12919. [PMID: 34884723 DOI: 10.3390/ijms222312919] [Reference Citation Analysis]